A5055112818- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Radiopharmaceutical Chemistry and Applications
- PARP inhibition in cancer therapy
- Testicular diseases and treatments
- MicroRNA in disease regulation
- Nutrition and Health in Aging
- RNA modifications and cancer
- Prostate Cancer Diagnosis and Treatment
- RNA Interference and Gene Delivery
- Economic and Financial Impacts of Cancer
- Urologic and reproductive health conditions
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Genomics and Diagnostics
- Acute Myeloid Leukemia Research
- Cancer, Lipids, and Metabolism
- Hematological disorders and diagnostics
- Cancer, Stress, Anesthesia, and Immune Response
- Metastasis and carcinoma case studies
- Bone and Joint Diseases
- Urological Disorders and Treatments
- Infectious Disease Case Reports and Treatments
- Colorectal Cancer Treatments and Studies
- Cancer Diagnosis and Treatment
University of Washington
2016-2025
Fred Hutch Cancer Center
2016-2025
Seattle Cancer Care Alliance
2017-2022
University of Washington Medical Center
2021
Cancer Research Center
2017
Dartmouth–Hitchcock Medical Center
2010
Dartmouth College
2010
University of Copenhagen
2010
Aalborg University
2010
Northwestern University
2008
Abstract Purpose: High-throughput profiling experiments have linked altered expression of microRNAs (miRNA) to different types cancer. Tumor tissues are a heterogeneous mixture not only cancer cells, but also supportive and reactive tumor microenvironment elements. To clarify the clinical significance miRNA in solid tumors, we developed sensitive fluorescence-based situ hybridization (ISH) method visualize accumulation within individual cells formalin-fixed, paraffin-embedded tissue...
PURPOSE Germline mutations in DNA repair genes are present approximately 10% of men with metastatic prostate cancer (mPC), and guidelines recommend genetic germline testing. Notable barriers exist, including access to counseling, insurance coverage, out-of-pocket costs. The GENTleMEN study was designed determine the feasibility an Internet-based, patient-driven testing approach for mPC. PATIENTS AND METHODS In this prospective cohort study, mPC provided informed consent via Internet-based...
While
5075 Background: Lutetium-177 prostate-specific membrane antigen ( 177 Lu-PSMA-617) is a life-prolonging treatment approved by the FDA in metastatic castration-resistant prostate cancer (mCRPC), at very late stage when there frequently reduced bone marrow reserve. We aim to report incidence of hematologic toxicity during and potential risk factors single-center study. Methods: This retrospective single-institution case series included mCRPC patients who underwent least one cycle Lu-PSMA-617...
769 Background: Cisplatin-based chemotherapy (CT) prior to radical cystectomy (RC) + perioperative anti-PDL1 improves pathologic complete response rates (pCR) and survival in MIBC with predominant UC. Outcomes are poorer the 5-10% of pure/predominant non-UC histology. Thus, optimizing neoadjuvant therapy for these patients (pts) is critical. Pembro monotherapy has induced promising pCR histologic subtypes (PURE-01 trial). We hypothesized that aMVAC pembro would be safe effective conducted a...
Abstract Background: A subset of aUCs harbor ERBB2 alterations. While anti-HER2 therapies in HER2-over-expressing aUC have been promising, relationships between alterations and response to other systemic are unclear. Based on available data, we hypothesized that ERBB2-altered would respond less favorably immune checkpoint inhibitor (ICI), enfortumab vedotin (EV), sacituzumab govitecan (SG) than ERBB2-wildtype aUC. Methods: This single-center retrospective study included patients (pts)...
BACKGROUND: Plasmacytoid urothelial carcinoma is a rare bladder cancer variant with scarce data on outcomes and prognostic factors. OBJECTIVE: We report our institutional experience this histology to determine response neoadjuvant chemotherapy, definitive surgery survival. METHODS: conducted retrospective chart review of consecutive patients plasmacytoid, as well conventional (for comparison) seen in institution (2007– 2018). Baseline characteristics, clinicopathologic treatment were...
The VISION and TheraP trials introduced different PET-based criteria for patient selection treatment with
Abstract Background Among men with metastatic prostate cancer, about 10% have germline alterations in DNA damage response genes. Most studies examined BRCA2 alone or an aggregate of BRCA1/2 and ATM . Emerging data suggest that mutations may distinct biology warrant individual evaluation. The objective this study is to determine whether cancer systemic therapies differs between (g ATM) BRCA2) Methods This international multicenter retrospective matched cohort harboring g PSA 50 (≥50% decline...
Abstract Background Localized prostate cancers (PCs) may resist neoadjuvant androgen receptor (AR)‐targeted therapies as a result of persistent intraprostatic androgens arising through upregulation steroidogenic enzymes. Therefore, we sought to evaluate clinical effects indomethacin (Indo), which inhibits the enzyme AKR1C3, in addition combinatorial anti‐androgen blockade, men with high‐risk PC undergoing radical prostatectomy (RP). Methods This was an open label, single‐site, Phase II trial...
5055 Background: LuPSMA, a radioligand targeting the cell surface protein PSMA, is approved for men with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) following an androgen receptor (AR)-signaling inhibitor (ARSI) and docetaxel. DNA damage repair gene (DDR) mutations are common in mCRPC, given that ionizing radiation induces damage, we hypothesized presence of these alterations could associate improved clinical outcomes to LuPSMA. Data also suggests DDR may correlate...
40 Background: LuPSMA is a newly established treatment in patients with mCRPC, but PSA and survival outcomes vary widely, predictors of responses are needed. delivers radiation to tumor tissues that can also be imaged SPECT/CT which provides semiquantitative estimates TTV identification NLs. This study investigates the use early cycles predict outcomes. Methods: Between June December 2022, mCRPC who initiated 2 nd cycle 24 hours post-treatment were retrospectively reviewed. We evaluated...
Lu-PSMA-617 (LuPSMA) is a newly established treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), but survival outcomes vary widely, and predictors of responses are needed. This study investigated the role total tumor volumes (TTVs) new lesions (NLs) determined by LuPSMA SPECT/CT in early cycles to predict subsequent real-world practice setting.